Insys Therapeutics (INRX) Files $55M IPO

Insys Therapeutics, Inc. (Nasdaq: INRX) filed a registration statement with the U.S. Securities and Exchange Commission today for an Initial Public Offering of their Common Stock. The proposed maximum aggregate offering price is $55 million. The company has filed to list their shares on the Nasdaq Global Market under the ticker "INRX."

The offering is being made through Wells Fargo Securities, JMP Securities, and Oppenheimer & Co.

Insys Therapeutics is a specialty pharmaceutical company that develops and seeks to commercialize innovative pharmaceutical products that target the unmet needs of cancer patients, with an initial focus on cancer-supportive care.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• SEC plans crypto investment regime and tokenized stock exemption - Bloomberg
• National Fuel Gas Company (NFG) files mixed shelf
• Blue Owl Capital prices $750M senior notes offering at 6.750%